The Japanese government on March 7 announced new NHI prices for the FY2025 drug price revision, effective April 1. With…
REGULATORY
MHLW to Set AI Limit for Atomoxetine’s Nitrosamine Impurities at 100 ng/Day
Japan will set an acceptable intake (AI) limit of 100 ng per day for N-nitroso-atomoxetine, a potentially carcinogenic nitrosamine, for the ADHD drug atomoxetine after the substance was found in some of the API used in a product marketed by…
To read the full story
Related Article
- Strattera Stock Expected to Run Out as Lilly's Talks with Regulators Drag On
March 24, 2025
- Strattera and All Generic Versions Now under Supply Restrictions in Japan
December 17, 2024
- All Versions of Lilly’s Strattera under Restricted Supplies in Japan
November 26, 2024
- Shipment Curbs Growing for Strattera Generics amid Nitrosamine Issues
November 18, 2024
- Lilly Japan Halts Manufacturing of Strattera over Nitrosamine Impurities
November 14, 2024
- Sawai Joins List of Atomoxetine Recalls after Establishing Test Model
September 27, 2024
- Don’t Stop Taking Atomoxetine at Own Discretion: MHLW to Patients
September 4, 2024
REGULATORY
- MHLW Flags Risk of Eye Disorders Associated with Tivdak upon Approval
March 31, 2025
- Daisuke Koga Named Head of PMDA’s International Office
March 31, 2025
- AMED Ties Up with Korea’s Govt Backed Research Institute
March 31, 2025
- Sakigake Tag Withdrawn for Boehringer, AbbVie APIs
March 31, 2025
- Japan Jittery over Mass Layoffs at FDA, though HHS Says Reviewers Won’t Be Affected
March 31, 2025
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…